Loading stock data…
Absci Corporation (ABSI)
$10.89+0.68 (+6.66%)
Market ClosedLast close Jun 26
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Absci Corporation in the Healthcare sector is trading at $11.11 with a market capitalization of $926M. Wall Street consensus targets $12.40 (10 analysts), implying a +11.7% move over the next 12 months. The stock is currently near its 52-week high of $12.04, remaining 183.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $215,000↓ | $650,000↑ | $378,000↓ | $593,000↓ | $1.18M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$30.85M↑ | -$36.14M↓ | -$30.15M↑ | -$31.39M↓ | -$27.73M |
| Net Income | -$29.60M↓ | -$29.56M↓ | -$28.71M↑ | -$30.57M↓ | -$26.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bow...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$926.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-68.87%
Volume
Today's trading volume
13.45M
Recent News
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
Absci Corporation stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program....
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Amid the debut of positive Phase I data, the biotech will push its lead asset further down the clinical pipeline in endometriosis and pattern hair loss.
Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?
Earlier this week, Absci Corporation reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into a multiple ascending dose stage. On the heels of these results, Absci also completed a roughly US$100.00 million follow-on equity offering backed by Eli Lilly & Company and other institutional investors, underscoring external confidence in the ABS-201 program...
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study
Absci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.